-
1
-
-
7444231093
-
Practical guidelines to interpret plasma concentrations of antiretroviral drugs
-
Kappelhoff BS, Crommentuyn KML, de Maat MMR, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004;43(13):845-53.
-
(2004)
Clin Pharmacokinet
, vol.43
, Issue.13
, pp. 845-853
-
-
Kappelhoff, B.S.1
Crommentuyn, K.M.L.2
De Maat, M.M.R.3
-
2
-
-
13244298666
-
Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review
-
De Jonge ME, Huitema ADR, Schellens JHM, et al. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44(2):147-73.
-
(2005)
Clin Pharmacokinet
, vol.44
, Issue.2
, pp. 147-173
-
-
De Jonge, M.E.1
Huitema, A.D.R.2
Schellens, J.H.M.3
-
3
-
-
84949176834
-
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
-
Q.A. Xu T.L. Madden (eds) Springer Boston
-
Decosterd L, Dahmane E, Neeman M, et al. Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: a clinical pharmacology laboratory perspective. In: Xu QA, Madden TL, editors. LC-MS in drug bioanalysis. Boston: Springer; 2012. p. 197-250.
-
(2012)
LC-MS in Drug Bioanalysis
, pp. 197-250
-
-
Decosterd, L.1
Dahmane, E.2
Neeman, M.3
-
4
-
-
84869381780
-
Evidence for therapeutic drug monitoring of targeted anticancer therapies
-
Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012;30(32):4017-25.
-
(2012)
J Clin Oncol
, vol.30
, Issue.32
, pp. 4017-4025
-
-
Gao, B.1
Yeap, S.2
Clements, A.3
-
5
-
-
79953004875
-
Therapeutic drug monitoring in oncology: Does it have a future?
-
McMahon G, O'Connor R. Therapeutic drug monitoring in oncology: does it have a future? Bioanalysis. 2009;1(3):507-11.
-
(2009)
Bioanalysis
, vol.1
, Issue.3
, pp. 507-511
-
-
McMahon, G.1
O'Connor, R.2
-
6
-
-
84874148548
-
Without therapeutic drug monitoring, there is no personalized cancer care
-
Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther. 2013;93(3):228-30.
-
(2013)
Clin Pharmacol Ther
, vol.93
, Issue.3
, pp. 228-230
-
-
Beumer, J.H.1
-
7
-
-
33646135276
-
Tyrosine kinase - Role and significance in cancer
-
1074718
-
Paul MK, Mukhopadhyay AK. Tyrosine kinase - role and significance in cancer. Int J Med Sci. 2004;1(2):101-15.
-
(2004)
Int J Med Sci
, vol.1
, Issue.2
, pp. 101-115
-
-
Paul, M.K.1
Mukhopadhyay, A.K.2
-
8
-
-
0008348082
-
-
European Medicines Agency (EMA) Accessed 8 Jan 2014
-
European Medicines Agency (EMA). European Public Assessment Reports. http://www.ema.europa.eu/ema. Accessed 8 Jan 2014.
-
European Public Assessment Reports
-
-
-
9
-
-
84899119611
-
-
US Food and Drug Administration. http://www.fda.gov. Accessed 8 Jan 2014
-
US Food and Drug Administration. http://www.fda.gov. Accessed 8 Jan 2014.
-
-
-
-
10
-
-
79953077853
-
Moving towards dose individualization of tyrosine kinase inhibitors
-
Klümpen H-J, Samer CF, Mathijssen RHJ, et al. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37(4):251-60.
-
(2011)
Cancer Treat Rev
, vol.37
, Issue.4
, pp. 251-260
-
-
Klümpen, H.-J.1
Samer, C.F.2
Mathijssen, R.H.J.3
-
12
-
-
84899067370
-
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care
-
Epub 2013 Dec 3
-
Lankheet NAG, Knapen LM, Schellens JHM, et al. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit. Epub 2013 Dec 3.
-
Ther Drug Monit
-
-
Nag, L.1
Knapen, L.M.2
Schellens, J.H.M.3
-
13
-
-
84885021526
-
Clinical pharmacokinetics of tyrosine kinase inhibitors: Implications for therapeutic drug monitoring
-
Josephs DH, Fisher DS, Spicer J, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit. 2013;35(5):562-87.
-
(2013)
Ther Drug Monit
, vol.35
, Issue.5
, pp. 562-587
-
-
Josephs, D.H.1
Fisher, D.S.2
Spicer, J.3
-
15
-
-
84876993943
-
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib
-
Rini BI, de La Motte Rouge T, Harzstark AL, et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer. 2013;11(2):107-14.
-
(2013)
Clin Genitourin Cancer
, vol.11
, Issue.2
, pp. 107-114
-
-
Rini, B.I.1
De La Motte Rouge, T.2
Harzstark, A.L.3
-
16
-
-
77649125649
-
Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC) [abstract no. 5045]
-
Rixe O, Dutcher J, Motzer R, et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC) [abstract no. 5045]. J Clin Oncol. 2009;27:15S.
-
(2009)
J Clin Oncol
, vol.27
-
-
Rixe, O.1
Dutcher, J.2
Motzer, R.3
-
17
-
-
84880157519
-
Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis
-
Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53(5):491-504.
-
(2013)
J Clin Pharmacol
, vol.53
, Issue.5
, pp. 491-504
-
-
Rini, B.I.1
Garrett, M.2
Poland, B.3
-
18
-
-
79957909038
-
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors
-
Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841-9.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.11
, pp. 3841-3849
-
-
Rini, B.I.1
Schiller, J.H.2
Fruehauf, J.P.3
-
19
-
-
84884949662
-
Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study [abstract no. LBA349]
-
Rini BI, Gruenwald V, Fishman MN, et al. Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): unblinded results from a randomized phase II study [abstract no. LBA349]. J Clin Oncol. 2013;31(suppl 6).
-
(2013)
J Clin Oncol.
, vol.31
, Issue.SUPPL. 6
-
-
Rini, B.I.1
Gruenwald, V.2
Fishman, M.N.3
-
20
-
-
84886719423
-
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial
-
Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233-42.
-
(2013)
Lancet Oncol
, vol.14
, Issue.12
, pp. 1233-1242
-
-
Rini, B.I.1
Melichar, B.2
Ueda, T.3
-
21
-
-
84857465780
-
Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management
-
Wood LS, Gornell S, Rini BI. Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management. Community Oncol. 2012;9(2):46-55.
-
(2012)
Community Oncol
, vol.9
, Issue.2
, pp. 46-55
-
-
Wood, L.S.1
Gornell, S.2
Rini, B.I.3
-
22
-
-
79952773320
-
Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients [abstract no. 2596]
-
Tan W, Wilner KD, Bang Y, et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients [abstract no. 2596]. J Clin Oncol. 2010;28(15 suppl).
-
(2010)
J Clin Oncol.
, vol.28
, Issue.15 SUPPL.
-
-
Tan, W.1
Wilner, K.D.2
Bang, Y.3
-
23
-
-
37549059613
-
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
-
Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 Pt 1):3314-22.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.12
, pp. 3314-3322
-
-
Christensen, J.G.1
Zou, H.Y.2
Arango, M.E.3
-
24
-
-
79957487193
-
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
-
Costa DB, Kobayashi S. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):2011-3.
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
, pp. 2011-2013
-
-
Costa, D.B.1
Kobayashi, S.2
-
25
-
-
84863116231
-
Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models
-
Yamazaki S, Vicini P, Shen Z, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther. 2012;340(3):549-57.
-
(2012)
J Pharmacol Exp Ther
, vol.340
, Issue.3
, pp. 549-557
-
-
Yamazaki, S.1
Vicini, P.2
Shen, Z.3
-
26
-
-
84877018103
-
Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: A case study of anticancer drug, crizotinib
-
3675733
-
Yamazaki S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J. 2013;15(2):354-66.
-
(2013)
AAPS J
, vol.15
, Issue.2
, pp. 354-366
-
-
Yamazaki, S.1
-
27
-
-
84873974299
-
Crizotinib: A new treatment option for ALK-positive non-small cell lung cancer
-
O'Bryant CL, Wenger SD, Kim M, et al. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother. 2013;47(2):189-97.
-
(2013)
Ann Pharmacother
, vol.47
, Issue.2
, pp. 189-197
-
-
O'Bryant, C.L.1
Wenger, S.D.2
Kim, M.3
-
28
-
-
77955174967
-
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract no. 3]
-
Bang Y, Kwak E, Shaw A, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract no. 3]. J Clin Oncol. 2010;28(18 suppl).
-
(2010)
J Clin Oncol.
, vol.28
, Issue.18 SUPPL.
-
-
Bang, Y.1
Kwak, E.2
Shaw, A.3
-
29
-
-
78649281412
-
Activity of crizotinib in patients with non-small cell lung cancer
-
Abraham J. Activity of crizotinib in patients with non-small cell lung cancer. Commun Oncol. 2010;7(10):443-4.
-
(2010)
Commun Oncol
, vol.7
, Issue.10
, pp. 443-444
-
-
Abraham, J.1
-
30
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
3014291
-
Kwak EL, Bang YJ, Camidge R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-703.
-
(2010)
N Engl J Med
, vol.363
, Issue.18
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, R.3
-
31
-
-
79955036989
-
Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
-
Bouchet S, Chauzit E, Ducint D, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta. 2011;412(11-12):1060-7.
-
(2011)
Clin Chim Acta
, vol.412
, Issue.11-12
, pp. 1060-1067
-
-
Bouchet, S.1
Chauzit, E.2
Ducint, D.3
-
32
-
-
84878999947
-
Differential effects of dosing regimen on the safety and efficacy of dasatinib: Retrospective exposure-response analysis of a phase III study
-
Wang X, Roy A, Hochhaus A, et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study. Clin Pharmacol Adv Appl. 2013;5:85-97.
-
(2013)
Clin Pharmacol Adv Appl
, vol.5
, pp. 85-97
-
-
Wang, X.1
Roy, A.2
Hochhaus, A.3
-
33
-
-
81455139201
-
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients
-
Pirro E, De Francia S, De Martino F, et al. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. J Chromatogr Sci. 2011;49(10):753-7.
-
(2011)
J Chromatogr Sci
, vol.49
, Issue.10
, pp. 753-757
-
-
Pirro, E.1
De Francia, S.2
De Martino, F.3
-
34
-
-
33645221739
-
Dasatinib (BMS-354825): A multitargeted kinase inhibitor with activity against multiple myeloma
-
Deng Q, Mitsiades N, Negri J, et al. Dasatinib (BMS-354825): a multitargeted kinase inhibitor with activity against multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2005;106:Abstract 1571.
-
(2005)
Blood (ASH Annual Meeting Abstracts).
, vol.106
, pp. 1571
-
-
Deng, Q.1
Mitsiades, N.2
Negri, J.3
-
35
-
-
43949122895
-
Potent transient inhibition of BCR-ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: Implications for patient management and drug development
-
Shah NP, Nicoll JM, Bleickardt E, et al. Potent transient inhibition of BCR-ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: implications for patient management and drug development. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 2166.
-
(2006)
Blood (ASH Annual Meeting Abstracts).
, vol.108
, pp. 2166
-
-
Shah, N.P.1
Nicoll, J.M.2
Bleickardt, E.3
-
36
-
-
33845723163
-
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
-
Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006;12(23):7180-6.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.23
, pp. 7180-7186
-
-
Luo, F.R.1
Yang, Z.2
Camuso, A.3
-
37
-
-
38949134552
-
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
-
Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14(2):352-9.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.2
, pp. 352-359
-
-
Brave, M.1
Goodman, V.2
Kaminskas, E.3
-
38
-
-
55949102580
-
Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract no. 3590]
-
Wang X, Hochhaus A, Kantarjian HM, et al. Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract no. 3590]. J Clin Oncol. 2008;26(15 suppl).
-
(2008)
J Clin Oncol.
, vol.26
, Issue.15 SUPPL.
-
-
Wang, X.1
Hochhaus, A.2
Kantarjian, H.M.3
-
39
-
-
84894089305
-
Pharmacologic monitoring of dasatinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) identifies patients at higher risk of pleural effusion: A sub-analysis of the OPTIM-Dasatinib Trial
-
Rousselot P, Mollica L, Etienne G, et al. Pharmacologic monitoring of dasatinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) identifies patients at higher risk of pleural effusion: a sub-analysis of the OPTIM-Dasatinib Trial. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 3770.
-
(2012)
Blood (ASH Annual Meeting Abstracts)
, vol.120
, pp. 3770
-
-
Rousselot, P.1
Mollica, L.2
Etienne, G.3
-
40
-
-
80053278339
-
Erlotinib "dosing-to-rash": A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
-
3185947
-
Mita AC, Papadopoulos K, de Jonge MJA, et al. Erlotinib "dosing-to-rash": a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer. 2011;105(7):938-44.
-
(2011)
Br J Cancer
, vol.105
, Issue.7
, pp. 938-944
-
-
Mita, A.C.1
Papadopoulos, K.2
De Jonge, M.J.A.3
-
41
-
-
4344646459
-
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
-
Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3238-47.
-
(2004)
J Clin Oncol
, vol.22
, Issue.16
, pp. 3238-3247
-
-
Pérez-Soler, R.1
Chachoua, A.2
Hammond, L.A.3
-
42
-
-
68749095215
-
Population pharmacokinetics of erlotinib and its pharmacokinetic/ pharmacodynamic relationships in head and neck squamous cell carcinoma
-
Thomas F, Rochaix P, White-Koning M, et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer. 2009;45(13):2316-23.
-
(2009)
Eur J Cancer
, vol.45
, Issue.13
, pp. 2316-2323
-
-
Thomas, F.1
Rochaix, P.2
White-Koning, M.3
-
43
-
-
34047190928
-
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer
-
Calvo E, Malik SN, Siu LL, et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol. 2007;18(4):761-7.
-
(2007)
Ann Oncol
, vol.18
, Issue.4
, pp. 761-767
-
-
Calvo, E.1
Malik, S.N.2
Siu, L.L.3
-
44
-
-
1842772526
-
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
-
Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77-85.
-
(2004)
J Clin Oncol
, vol.22
, Issue.1
, pp. 77-85
-
-
Soulieres, D.1
Senzer, N.N.2
Vokes, E.E.3
-
45
-
-
77954425045
-
Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations
-
2893286
-
Yeo W, Riely GJ, Yeap BY, et al. Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations. J Thorac Oncol. 2010;5(7):1048-53.
-
(2010)
J Thorac Oncol
, vol.5
, Issue.7
, pp. 1048-1053
-
-
Yeo, W.1
Riely, G.J.2
Yeap, B.Y.3
-
46
-
-
84899097625
-
-
Accessed 20 Mar 2013
-
Erlotinib EMA scientific discussion. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000618/WC500033991.pdf. Accessed 20 Mar 2013.
-
Erlotinib EMA Scientific Discussion
-
-
-
47
-
-
0030774045
-
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
-
Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57(21):4838-48.
-
(1997)
Cancer Res
, vol.57
, Issue.21
, pp. 4838-4848
-
-
Moyer, J.D.1
Barbacci, E.G.2
Iwata, K.K.3
-
48
-
-
0032695910
-
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
-
Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999;291(2):739-48.
-
(1999)
J Pharmacol Exp Ther
, vol.291
, Issue.2
, pp. 739-748
-
-
Pollack, V.A.1
Savage, D.M.2
Baker, D.A.3
-
49
-
-
0035398631
-
Phase i and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
-
Hidalgo M, Siu LL, Nemunaitis J. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19(13):3267-79.
-
(2001)
J Clin Oncol
, vol.19
, Issue.13
, pp. 3267-3279
-
-
Hidalgo, M.1
Siu, L.L.2
Nemunaitis, J.3
-
50
-
-
0035215722
-
Selected novel anticancer treatments targeting cell signaling proteins
-
Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
-
(2001)
Oncologist
, vol.6
, Issue.6
, pp. 517-537
-
-
Elsayed, Y.A.1
Sausville, E.A.2
-
51
-
-
10944226719
-
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection
-
Zhang W, Siu LL, Moore MJ, et al. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J Chromatogr B. 2005;814(1):143-7.
-
(2005)
J Chromatogr B
, vol.814
, Issue.1
, pp. 143-147
-
-
Zhang, W.1
Siu, L.L.2
Moore, M.J.3
-
52
-
-
34250208469
-
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study
-
Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007;25(16):2178-83.
-
(2007)
J Clin Oncol
, vol.25
, Issue.16
, pp. 2178-2183
-
-
Siu, L.L.1
Soulieres, D.2
Chen, E.X.3
-
53
-
-
39749089941
-
A phase i and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies
-
Chiorean EG, Porter JM, Foster AE, et al. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res. 2008;14(4):1131-7.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.4
, pp. 1131-1137
-
-
Chiorean, E.G.1
Porter, J.M.2
Foster, A.E.3
-
54
-
-
0037674062
-
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
-
Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21(10):1980-7.
-
(2003)
J Clin Oncol
, vol.21
, Issue.10
, pp. 1980-1987
-
-
Cohen, E.E.W.1
Rosen, F.2
Stadler, W.M.3
-
55
-
-
38549167111
-
Clinical research of EGFR inhibitors and related dermatological toxicities
-
Perez-Soler R, van Cutsem E. Clinical research of EGFR inhibitors and related dermatological toxicities. Oncology (Williston Park). 2007;21(11 suppl 5):10-6.
-
(2007)
Oncology (Williston Park)
, vol.21
, Issue.11 SUPPL. 5
, pp. 10-16
-
-
Perez-Soler, R.1
Van Cutsem, E.2
-
56
-
-
84892893614
-
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)
-
Tiseo M, Andreoli R, Gelsomino F, et al. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2014;83:265-71.
-
(2014)
Lung Cancer
, vol.83
, pp. 265-271
-
-
Tiseo, M.1
Andreoli, R.2
Gelsomino, F.3
-
57
-
-
33746678595
-
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer
-
Lu J-F, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006;80(2):136-45.
-
(2006)
Clin Pharmacol Ther
, vol.80
, Issue.2
, pp. 136-145
-
-
Lu, J.-F.1
Eppler, S.M.2
Wolf, J.3
-
58
-
-
80052435929
-
The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib
-
Zhao Y-Y, Li S, Zhang Y, et al. The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol. 2011;28(3):697-702.
-
(2011)
Med Oncol
, vol.28
, Issue.3
, pp. 697-702
-
-
Zhao, Y.-Y.1
Li, S.2
Zhang, Y.3
-
59
-
-
77956264432
-
Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer
-
Nakamura Y, Sano K, Soda H. Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1404-9.
-
(2010)
J Thorac Oncol
, vol.5
, Issue.9
, pp. 1404-1409
-
-
Nakamura, Y.1
Sano, K.2
Soda, H.3
-
60
-
-
20044370274
-
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
-
Mohamed MK, Ramalingam S, Lin Y, et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2005;16(5):780-5.
-
(2005)
Ann Oncol
, vol.16
, Issue.5
, pp. 780-785
-
-
Mohamed, M.K.1
Ramalingam, S.2
Lin, Y.3
-
61
-
-
33646381931
-
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126
-
West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006;24(12):1807-13.
-
(2006)
J Clin Oncol
, vol.24
, Issue.12
, pp. 1807-1813
-
-
West, H.L.1
Franklin, W.A.2
McCoy, J.3
-
62
-
-
84876565639
-
Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients
-
3569587
-
Sugiura Y, Nemoto E, Kawai O, et al. Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. Springerplus. 2013;2(1):22.
-
(2013)
Springerplus
, vol.2
, Issue.1
, pp. 22
-
-
Sugiura, Y.1
Nemoto, E.2
Kawai, O.3
-
63
-
-
84866144502
-
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials
-
Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78(1):8-15.
-
(2012)
Lung Cancer
, vol.78
, Issue.1
, pp. 8-15
-
-
Petrelli, F.1
Borgonovo, K.2
Cabiddu, M.3
-
64
-
-
84865184491
-
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck
-
Perez CA, Song H, Raez LE, et al. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012;48(9):887-92.
-
(2012)
Oral Oncol
, vol.48
, Issue.9
, pp. 887-892
-
-
Perez, C.A.1
Song, H.2
Raez, L.E.3
-
65
-
-
34147174980
-
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
-
Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496-9.
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3496-3499
-
-
Picard, S.1
Titier, K.2
Etienne, G.3
-
66
-
-
43249083718
-
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study
-
Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022-8.
-
(2008)
Blood
, vol.111
, Issue.8
, pp. 4022-4028
-
-
Larson, R.A.1
Druker, B.J.2
Guilhot, F.3
-
67
-
-
78449312021
-
Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia
-
Takahashi N, Wakita H, Miura M, et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther. 2010;88(6):809-13.
-
(2010)
Clin Pharmacol Ther
, vol.88
, Issue.6
, pp. 809-813
-
-
Takahashi, N.1
Wakita, H.2
Miura, M.3
-
68
-
-
84870931711
-
Imatinib plasma trough levels in chronic myeloid leukaemia: Results of a multicentre study CSTI571AIL11TGLIVEC
-
Koren-Michowitz M, Volchek Y, Naparstek E, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol. 2012;30(4):200-5.
-
(2012)
Hematol Oncol
, vol.30
, Issue.4
, pp. 200-205
-
-
Koren-Michowitz, M.1
Volchek, Y.2
Naparstek, E.3
-
69
-
-
77952467377
-
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
-
Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-8.
-
(2010)
J Clin Oncol
, vol.28
, Issue.14
, pp. 2381-2388
-
-
Marin, D.1
Bazeos, A.2
Mahon, F.-X.3
-
70
-
-
77953952853
-
Integrating pharmacogenetics and therapeutic drug monitoring: Optimal dosing of imatinib as a case-example
-
Li-Wan-Po A, Farndon P, Craddock C, et al. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol. 2010;66(4):369-74.
-
(2010)
Eur J Clin Pharmacol
, vol.66
, Issue.4
, pp. 369-374
-
-
Li-Wan-Po, A.1
Farndon, P.2
Craddock, C.3
-
71
-
-
68849113721
-
Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: Comparing plasma levels of responders and non-responders
-
Singh N, Kumar L, Meena R, et al. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol. 2009;65(6):545-9.
-
(2009)
Eur J Clin Pharmacol
, vol.65
, Issue.6
, pp. 545-549
-
-
Singh, N.1
Kumar, L.2
Meena, R.3
-
72
-
-
78149357619
-
Relationship of serum imatinib trough level and response in CML patients: Long term follow-up
-
Awidi A, Ayed AO, Bsoul N, et al. Relationship of serum imatinib trough level and response in CML patients: long term follow-up. Leuk Res. 2010;34(12):1573-5.
-
(2010)
Leuk Res
, vol.34
, Issue.12
, pp. 1573-1575
-
-
Awidi, A.1
Ayed, A.O.2
Bsoul, N.3
-
73
-
-
67650306170
-
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors
-
Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27(19):3141-7.
-
(2009)
J Clin Oncol
, vol.27
, Issue.19
, pp. 3141-3147
-
-
Demetri, G.D.1
Wang, Y.2
Wehrle, E.3
-
74
-
-
77950369782
-
Imatinib plasma levels: Correlation with clinical benefit in GIST patients
-
2853086
-
Widmer N, Decosterd L, Csajka C, et al. Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br J Cancer. 2010;102(7):1198-9.
-
(2010)
Br J Cancer
, vol.102
, Issue.7
, pp. 1198-1199
-
-
Widmer, N.1
Decosterd, L.2
Csajka, C.3
-
75
-
-
84875078162
-
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours
-
Haouala A, Widmer N, Guidi M, et al. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. Br J Clin Pharmacol. 2013;75(4):1007-18.
-
(2013)
Br J Clin Pharmacol
, vol.75
, Issue.4
, pp. 1007-1018
-
-
Haouala, A.1
Widmer, N.2
Guidi, M.3
-
76
-
-
84874093024
-
Long-term prospective population PK study in GIST patients [letter]
-
Chatelut E, Gandia P, Gotta V, et al. Long-term prospective population PK study in GIST patients [letter]. Clin Cancer Res. 2013;19(4):949.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.4
, pp. 949
-
-
Chatelut, E.1
Gandia, P.2
Gotta, V.3
-
77
-
-
84867521054
-
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients
-
Eechoute K, Fransson MN, Reyners AK, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18(20):5780-7.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.20
, pp. 5780-5787
-
-
Eechoute, K.1
Fransson, M.N.2
Reyners, A.K.3
-
78
-
-
33750735723
-
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
-
Delbaldo C, Chatelut E, Ré M, et al. Pharmacokinetic- pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006;12(20 Pt 1):6073-8.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.20 PART 1
, pp. 6073-6078
-
-
Delbaldo, C.1
Chatelut, E.2
Ré, M.3
-
79
-
-
77953723830
-
24 Months update of the TOPS study: A phase III, randomized, open-label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP)
-
Baccarani M, Druker B, Cortes-Franco J, et al. 24 Months update of the TOPS study: a phase III, randomized, open-label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 337.
-
(2009)
Blood (ASH Annual Meeting Abstracts)
, vol.114
, pp. 337
-
-
Baccarani, M.1
Druker, B.2
Cortes-Franco, J.3
-
80
-
-
84856109375
-
The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors
-
Teng JFT, Mabasa VH, Ensom MHH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit. 2012;34(1):85-97.
-
(2012)
Ther Drug Monit
, vol.34
, Issue.1
, pp. 85-97
-
-
Teng, J.F.T.1
Mabasa, V.H.2
Ensom, M.H.H.3
-
81
-
-
34548830783
-
Therapeutic drug monitoring in CML patients on imatinib [letter]
-
(author reply 1701)
-
Blasdel C, Egorin MJ, Lagattuta TF, et al. Therapeutic drug monitoring in CML patients on imatinib [letter]. Blood. 2007;110(5):1699-701 (author reply 1701).
-
(2007)
Blood.
, vol.110
, Issue.5
, pp. 1699-1701
-
-
Blasdel, C.1
Egorin, M.J.2
Lagattuta, T.F.3
-
84
-
-
23944476155
-
Phase i safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23(23):5305-13.
-
(2005)
J Clin Oncol
, vol.23
, Issue.23
, pp. 5305-5313
-
-
Burris III, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
-
85
-
-
70350743116
-
A phase i and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies
-
3232441
-
Burris HA III, Taylor CW, Jones SF, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res. 2009;15(21):6702-8.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.21
, pp. 6702-6708
-
-
Burris III, H.A.1
Taylor, C.W.2
Jones, S.F.3
-
86
-
-
84879341555
-
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or intolerant CML from the East Japan CML Study Group (EJCML) trial: Evaluation of molecular responses by the BCR-ABL1 mutational status and plasma trough concentration
-
Takahashi N, Miura M, Kuroki J, et al. Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or intolerant CML from the East Japan CML Study Group (EJCML) trial: evaluation of molecular responses by the BCR-ABL1 mutational status and plasma trough concentration. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 1360.
-
(2012)
Blood (ASH Annual Meeting Abstracts).
, vol.120
, pp. 1360
-
-
Takahashi, N.1
Miura, M.2
Kuroki, J.3
-
87
-
-
84864285497
-
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase
-
Larson RA, Yin OQP, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68(5):723-33.
-
(2012)
Eur J Clin Pharmacol
, vol.68
, Issue.5
, pp. 723-733
-
-
Larson, R.A.1
Yin, O.Q.P.2
Hochhaus, A.3
-
88
-
-
84876712497
-
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
-
Giles FJ, Yin OQP, Sallas WM, et al. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol. 2013;69(4):813-23.
-
(2013)
Eur J Clin Pharmacol
, vol.69
, Issue.4
, pp. 813-823
-
-
Giles, F.J.1
Yin, O.Q.P.2
Sallas, W.M.3
-
89
-
-
34447322566
-
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
-
Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012-21.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.7
, pp. 2012-2021
-
-
Kumar, R.1
Knick, V.B.2
Rudolph, S.K.3
-
90
-
-
67449164582
-
Phase i trial of pazopanib in patients with advanced cancer
-
Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220-7.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.12
, pp. 4220-4227
-
-
Hurwitz, H.I.1
Dowlati, A.2
Saini, S.3
-
91
-
-
84984538873
-
Phase i dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
-
Yau T, Chen P-J, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011;17(21):6914-23.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.21
, pp. 6914-6923
-
-
Yau, T.1
Chen, P.-J.2
Chan, P.3
-
92
-
-
78650413534
-
Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC) [abstract no. 3048]
-
Suttle B, Ball HA, Molimard M, et al. Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC) [abstract no. 3048]. J Clin Oncol. 2010;28(15 suppl).
-
(2010)
J Clin Oncol.
, vol.28
, Issue.15 SUPPL.
-
-
Suttle, B.1
Ball, H.A.2
Molimard, M.3
-
93
-
-
84898697355
-
Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma [abstract no. 345]
-
Lin Y, Ball HA, Suttle B, et al. Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma [abstract no. 345]. J Clin Oncol. 2011;29(7 suppl).
-
(2011)
J Clin Oncol.
, vol.29
, Issue.7 SUPPL.
-
-
Lin, Y.1
Ball, H.A.2
Suttle, B.3
-
94
-
-
84899071932
-
-
Pazopanib-EMA.
-
Pazopanib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001141/WC500094272.pdf. Accessed 21 Mar 2013.
-
-
-
-
96
-
-
34247857540
-
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase i trials in patients with advanced refractory solid tumors
-
Strumberg D, Clark J, Awada A. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12(4):426-37.
-
(2007)
Oncologist
, vol.12
, Issue.4
, pp. 426-437
-
-
Strumberg, D.1
Clark, J.2
Awada, A.3
-
97
-
-
44449142019
-
Phase i and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
-
Minami H, Kawada K, Ebi H, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008;99(7):1492-8.
-
(2008)
Cancer Sci
, vol.99
, Issue.7
, pp. 1492-1498
-
-
Minami, H.1
Kawada, K.2
Ebi, H.3
-
98
-
-
67650293850
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
-
2716936
-
Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133-40.
-
(2009)
J Clin Oncol
, vol.27
, Issue.19
, pp. 3133-3140
-
-
Maki, R.G.1
D'Adamo, D.R.2
Keohan, M.L.3
-
99
-
-
84864626085
-
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells
-
Kuckertz M, Patz M, Veldurthy A, et al. Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. Onkologie. 2012;35(7-8):420-6.
-
(2012)
Onkologie
, vol.35
, Issue.7-8
, pp. 420-426
-
-
Kuckertz, M.1
Patz, M.2
Veldurthy, A.3
-
100
-
-
46449088111
-
Metabolism and disposition of dasatinib after oral administration to humans
-
Christopher L, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36(7):1357-64.
-
(2008)
Drug Metab Dispos
, vol.36
, Issue.7
, pp. 1357-1364
-
-
Christopher, L.1
Cui, D.2
Wu, C.3
-
101
-
-
84865053668
-
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: A preliminary study
-
3418266
-
Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One. 2012;7(8):e42875.
-
(2012)
PLoS One
, vol.7
, Issue.8
, pp. 42875
-
-
Boudou-Rouquette, P.1
Narjoz, C.2
Golmard, J.L.3
-
102
-
-
62949189153
-
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
-
Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49(4):1109-14.
-
(2009)
J Pharm Biomed Anal
, vol.49
, Issue.4
, pp. 1109-1114
-
-
Blanchet, B.1
Billemont, B.2
Cramard, J.3
-
103
-
-
84893332573
-
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma
-
Fukudo M, Ito T, Mizuno T, et al. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet. 2014;53:185-96.
-
(2014)
Clin Pharmacokinet
, vol.53
, pp. 185-196
-
-
Fukudo, M.1
Ito, T.2
Mizuno, T.3
-
104
-
-
84866673261
-
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
-
Arrondeau J, Mir O, Boudou-Rouquette P, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30(5):2046-9.
-
(2012)
Invest New Drugs
, vol.30
, Issue.5
, pp. 2046-2049
-
-
Arrondeau, J.1
Mir, O.2
Boudou-Rouquette, P.3
-
105
-
-
79954431917
-
A phase i open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
-
3064895
-
Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-64.
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, Issue.4
, pp. 751-764
-
-
Tolcher, A.W.1
Appleman, L.J.2
Shapiro, G.I.3
-
106
-
-
77953033291
-
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis
-
Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66(2):357-71.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, Issue.2
, pp. 357-371
-
-
Houk, B.E.1
Bello, C.L.2
Poland, B.3
-
107
-
-
84899098253
-
-
Sunitinib-EMA.
-
Sunitinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000687/WC500057737.pdf. Accessed 16 Jul 2013.
-
-
-
-
108
-
-
33644847440
-
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
-
Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35.
-
(2006)
J Clin Oncol
, vol.24
, Issue.1
, pp. 25-35
-
-
Faivre, S.1
Delbaldo, C.2
Vera, K.3
-
109
-
-
78549246206
-
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
-
Shirao K, Nishida T, Doi T, et al. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2009;28(6):866-75.
-
(2009)
Invest New Drugs
, vol.28
, Issue.6
, pp. 866-875
-
-
Shirao, K.1
Nishida, T.2
Doi, T.3
-
111
-
-
78650874372
-
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
-
Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471-8.
-
(2003)
Mol Cancer Ther
, vol.2
, Issue.5
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
-
112
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-37.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.1
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
-
113
-
-
9144274970
-
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
-
Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20(8):757-66.
-
(2003)
Clin Exp Metastasis
, vol.20
, Issue.8
, pp. 757-766
-
-
Murray, L.J.1
Abrams, T.J.2
Long, K.R.3
-
114
-
-
2442669093
-
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
-
Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2(10):1011-21.
-
(2003)
Mol Cancer Ther
, vol.2
, Issue.10
, pp. 1011-1021
-
-
Abrams, T.J.1
Murray, L.J.2
Pesenti, E.3
-
115
-
-
84899926811
-
Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors [abstract no. 2596]
-
Lankheet NAG, Kloth JSL, Gadellaa-van Hooijdonk CGM, et al. Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors [abstract no. 2596]. J Clin Oncol. 2012;30(15 suppl).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL.
-
-
Lankheet, N.A.G.1
Jsl, K.2
Gadellaa-Van Hooijdonk, C.G.M.3
-
116
-
-
67249147869
-
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
-
George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959-68.
-
(2009)
Eur J Cancer
, vol.45
, Issue.11
, pp. 1959-1968
-
-
George, S.1
Blay, J.Y.2
Casali, P.G.3
-
117
-
-
84861737588
-
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors
-
Li J, Gao J, Hong J, et al. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Future Oncol. 2012;8(5):617-24.
-
(2012)
Future Oncol
, vol.8
, Issue.5
, pp. 617-624
-
-
Li, J.1
Gao, J.2
Hong, J.3
-
118
-
-
0037102369
-
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
-
Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645-55.
-
(2002)
Cancer Res
, vol.62
, Issue.16
, pp. 4645-4655
-
-
Wedge, S.R.1
Ogilvie, D.J.2
Dukes, M.3
-
119
-
-
0037115405
-
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
-
Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284-90.
-
(2002)
Cancer Res
, vol.62
, Issue.24
, pp. 7284-7290
-
-
Carlomagno, F.1
Vitagliano, D.2
Guida, T.3
-
120
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
3724529
-
Flaherty KT, Puzanov I, Kim KB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-19.
-
(2010)
N Engl J Med
, vol.363
, Issue.9
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
122
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
3724515
-
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-14.
-
(2012)
N Engl J Med
, vol.366
, Issue.8
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
-
123
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
3549296
-
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
124
-
-
0037868167
-
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
-
Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol. 2003;21(11):2094-100.
-
(2003)
J Clin Oncol
, vol.21
, Issue.11
, pp. 2094-2100
-
-
Miller, V.A.1
Johnson, D.H.2
Krug, L.M.3
-
125
-
-
1542608328
-
Pharmacokinetics and pharmacodynamics of imatinib in a phase i trial with chronic myeloid leukemia patients
-
Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935-42.
-
(2004)
J Clin Oncol
, vol.22
, Issue.5
, pp. 935-942
-
-
Peng, B.1
Hayes, M.2
Resta, D.3
-
126
-
-
84859124139
-
Crizotinib: A novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
-
3232174
-
Ou S-HI. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-85.
-
(2011)
Drug des Devel Ther
, vol.5
, pp. 471-485
-
-
Ou, S.-H.1
-
127
-
-
37849012740
-
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals
-
Ling J, Fettner S, Lum BL, et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008;19(2):209-16.
-
(2008)
Anticancer Drugs
, vol.19
, Issue.2
, pp. 209-216
-
-
Ling, J.1
Fettner, S.2
Lum, B.L.3
-
128
-
-
84899058818
-
-
Gefitinib-EMA.
-
Gefitinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001016/WC500036358.pdf. Accessed 10 Jun 2013.
-
-
-
-
129
-
-
84899064349
-
-
Imatinib-EMA.
-
Imatinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000406/WC500022207.pdf. Accessed 26 Aug 2012.
-
-
-
-
130
-
-
62449338902
-
Effects of food on the relative bioavailability of lapatinib in cancer patients
-
Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27(8):1191-6.
-
(2009)
J Clin Oncol
, vol.27
, Issue.8
, pp. 1191-1196
-
-
Koch, K.M.1
Reddy, N.J.2
Cohen, R.B.3
-
131
-
-
84899082885
-
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
-
Epub 2013 Dec 19
-
Devriese LA, Koch KM, Mergui-Roelvink M, et al. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs. Epub 2013 Dec 19.
-
Invest New Drugs
-
-
Devriese, L.A.1
Koch, K.M.2
Mergui-Roelvink, M.3
-
132
-
-
84874182951
-
Playing Russian roulette with tyrosine kinase inhibitors
-
Szmulewitz RZ, Ratain MJ. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2012;93(3):242-4.
-
(2012)
Clin Pharmacol Ther
, vol.93
, Issue.3
, pp. 242-244
-
-
Szmulewitz, R.Z.1
Ratain, M.J.2
-
133
-
-
84899113720
-
-
Nilotinib-EMA.
-
Nilotinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000798/WC500034394.pdf. Accessed 14 Jun 0213.
-
-
-
-
134
-
-
84899046303
-
The effect of food on the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects [abstract no. 3167]
-
14S Jul
-
Smith RP, Kennedy S, Robertson J, et al. The effect of food on the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects [abstract no. 3167]. J Clin Oncol 2004 ASCO Annu Meet Proc (Post-Meeting Ed);22(14S Jul 15 Suppl).
-
J Clin Oncol 2004 ASCO Annu Meet Proc (Post-Meeting Ed)
, vol.22
, Issue.15 SUPPL.
-
-
Smith, R.P.1
Kennedy, S.2
Robertson, J.3
-
135
-
-
84899113216
-
-
Vemurafenib-EMA.
-
Vemurafenib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002409/WC500124317.pdf. Accessed 17 Jul 2013.
-
-
-
-
136
-
-
24944453855
-
Phase i trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results
-
Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474-83.
-
(2005)
J Clin Oncol
, vol.23
, Issue.24
, pp. 5474-5483
-
-
Rugo, H.S.1
Herbst, R.S.2
Liu, G.3
-
137
-
-
84899104067
-
-
Axitinib-EMA.
-
Axitinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/002406/WC500132188.pdf. Accessed 2 Jul 2013.
-
-
-
-
138
-
-
84864351085
-
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: Results from phase i studies in Japanese patients
-
3348450
-
Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 2012;30(3):1055-64.
-
(2012)
Invest New Drugs
, vol.30
, Issue.3
, pp. 1055-1064
-
-
Fujiwara, Y.1
Kiyota, N.2
Chayahara, N.3
-
139
-
-
84867398104
-
Phase i trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
-
3494447
-
Kozloff MF, Martin LP, Krzakowski M, et al. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer. 2012;107(8):1277-85.
-
(2012)
Br J Cancer
, vol.107
, Issue.8
, pp. 1277-1285
-
-
Kozloff, M.F.1
Martin, L.P.2
Krzakowski, M.3
-
140
-
-
84867400512
-
Phase i study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
-
3494424
-
Martin LP, Kozloff MF, Herbst RS, et al. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer. 2012;107(8):1268-76.
-
(2012)
Br J Cancer
, vol.107
, Issue.8
, pp. 1268-1276
-
-
Martin, L.P.1
Kozloff, M.F.2
Herbst, R.S.3
-
141
-
-
77957269382
-
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase i study in Japanese patients
-
Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010;101(4):963-8.
-
(2010)
Cancer Sci
, vol.101
, Issue.4
, pp. 963-968
-
-
Mukohara, T.1
Nakajima, H.2
Mukai, H.3
-
142
-
-
84899057651
-
-
Crizotinib-EMA.
-
Crizotinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002489/WC500134759.pdf. Accessed 19 Nov 2013.
-
-
-
-
143
-
-
84055203408
-
Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors [abstract no e13065]
-
Li C, Alvey C, Bello A, et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors [abstract no. e13065]. J Clin Oncol. 2011;29(15 suppl).
-
(2011)
J Clin Oncol.
, vol.29
, Issue.15 SUPPL.
-
-
Li, C.1
Alvey, C.2
Bello, A.3
-
144
-
-
84899079596
-
-
Dasatinib EMA.
-
Dasatinib EMA scientific discussion. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000709/WC500056995.pdf. Accessed 9 Jul 2013.
-
-
-
-
145
-
-
79952095727
-
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
-
Okusaka T, Furuse J, Funakoshi A, et al. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci. 2011;102(2):425-31.
-
(2011)
Cancer Sci
, vol.102
, Issue.2
, pp. 425-431
-
-
Okusaka, T.1
Furuse, J.2
Funakoshi, A.3
-
146
-
-
75749110539
-
A phase i trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
-
2940559
-
Raizer JJ, Abrey LE, Lassman AB, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010;12(1):87-94.
-
(2010)
Neuro Oncol
, vol.12
, Issue.1
, pp. 87-94
-
-
Raizer, J.J.1
Abrey, L.E.2
Lassman, A.B.3
-
147
-
-
33845680787
-
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
-
Li J, Karlsson MO, Brahmer J, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst. 2006;98(23):1714-23.
-
(2006)
J Natl Cancer Inst
, vol.98
, Issue.23
, pp. 1714-1723
-
-
Li, J.1
Karlsson, M.O.2
Brahmer, J.3
-
148
-
-
82455175183
-
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib
-
Horak J, White J, Harris AL, et al. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol. 2011;68(6):1485-95.
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, Issue.6
, pp. 1485-1495
-
-
Horak, J.1
White, J.2
Harris, A.L.3
-
149
-
-
84873056956
-
Activity-based kinase profiling of approved tyrosine kinase inhibitors
-
Kitagawa D, Yokota K, Gouda M, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18(2):110-22.
-
(2013)
Genes Cells
, vol.18
, Issue.2
, pp. 110-122
-
-
Kitagawa, D.1
Yokota, K.2
Gouda, M.3
-
150
-
-
67749101106
-
Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia
-
Kawaguchi T, Hamada A, Hirayama C, et al. Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol. 2009;89(5):642-8.
-
(2009)
Int J Hematol
, vol.89
, Issue.5
, pp. 642-648
-
-
Kawaguchi, T.1
Hamada, A.2
Hirayama, C.3
-
151
-
-
34547684260
-
Phase i pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors
-
Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res. 2007;13(15):4495-502.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.15
, pp. 4495-4502
-
-
Siegel-Lakhai, W.S.1
Beijnen, J.H.2
Vervenne, W.L.3
-
152
-
-
51549101729
-
A phase i and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer
-
Chu QSC, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 2008;14(14):4484-90.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.14
, pp. 4484-4490
-
-
Chu, Q.S.C.1
Cianfrocca, M.E.2
Goldstein, L.J.3
-
153
-
-
82455175175
-
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients
-
Rezai K, Urien S, Isambert N, et al. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol. 2011;68(6):1529-36.
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, Issue.6
, pp. 1529-1536
-
-
Rezai, K.1
Urien, S.2
Isambert, N.3
-
154
-
-
84899099079
-
-
Lapatinib-EMA.
-
Lapatinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000795/WC500044957.pdf. Accessed 17 Jul 2013.
-
-
-
-
155
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-51.
-
(2006)
N Engl J Med
, vol.354
, Issue.24
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
-
156
-
-
84879868783
-
Phase i study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group study
-
Shibata SI, Chung V, Synold TW, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013;19(13):3631-9.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.13
, pp. 3631-3639
-
-
Shibata, S.I.1
Chung, V.2
Synold, T.W.3
-
157
-
-
84899095642
-
-
Sorafenib-EMA.
-
Sorafenib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000690/WC500027704.pdf. Accessed 16 Jul 2013.
-
-
-
-
158
-
-
79960151990
-
Population pharmacokinetic analysis of sorafenib in patients with solid tumours
-
3162659
-
Jain L, Woo S, Gardner ER, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 2011;72(2):294-305.
-
(2011)
Br J Clin Pharmacol
, vol.72
, Issue.2
, pp. 294-305
-
-
Jain, L.1
Woo, S.2
Gardner, E.R.3
-
159
-
-
70350655546
-
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
-
2778527
-
Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer. 2009;101(9):1543-8.
-
(2009)
Br J Cancer
, vol.101
, Issue.9
, pp. 1543-1548
-
-
Novello, S.1
Scagliotti, G.V.2
Rosell, R.3
-
160
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329- 38.
-
(2006)
Lancet
, vol.368
, Issue.9544
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
-
161
-
-
37249072373
-
A phase i and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
-
Britten C, Kabbinavar F, Hecht J. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61:515-24.
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 515-524
-
-
Britten, C.1
Kabbinavar, F.2
Hecht, J.3
-
162
-
-
84899119863
-
-
Vandetanib-EMA.
-
Vandetanib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002315/WC500123555.pdf. Accessed 16 Jul 2013.
-
-
-
-
163
-
-
23844544081
-
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
-
Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16(8):1391-7.
-
(2005)
Ann Oncol
, vol.16
, Issue.8
, pp. 1391-1397
-
-
Holden, S.N.1
Eckhardt, S.G.2
Basser, R.3
-
164
-
-
33846844387
-
A phase i dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors
-
Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006;1(9):1002-9.
-
(2006)
J Thorac Oncol
, vol.1
, Issue.9
, pp. 1002-1009
-
-
Tamura, T.1
Minami, H.2
Yamada, Y.3
-
165
-
-
79956029711
-
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: An open-label, phase I, rising multiple-dose study
-
Zhang L, Li S, Zhang Y, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011;33(3):315-27.
-
(2011)
Clin Ther
, vol.33
, Issue.3
, pp. 315-327
-
-
Zhang, L.1
Li, S.2
Zhang, Y.3
|